Cyclacel pulls the plug on Daiichi-partnered chemo — 8 years after a failed PhIII in AML
10 Nov 2022
Phase 3License out/inClinical ResultClinical Trial Termination
Hovering around penny stock territory, New Jersey-based Cyclacel Pharmaceuticals $CYCC said yesterday it’s finally going to call it quits on a Daiichi Sankyo-partnered cancer drug candidate that saw a Phase III flop in acute myeloid leukemia in late 2014.
First licensed from Daiichi back in 2003, Cyclacel says it now wants to terminate the development of sapacitabine, and its license agreement with Daiichi on the drug “for commercial reasons,” with the termination effective by March 23, 2023.
Back in late 2014, a data and safety monitoring board called to halt that sapacitabine study in AML due to futility, but the company continued the trial into 2017, ultimately finding that it did not show an overall survival benefit. The median OS was 5.9 months on the study arm versus 5.7 months on the control arm (P = .8902), according to the results published last year.
The drug was also tested in mid-stage trials for other cancers like myelodysplastic syndromes and lung cancer.
Meanwhile, Cyclacel said in its earnings report yesterday that it’s also working on an ongoing Phase I/II study of oral fadraciclib in solid tumors and lymphoma, and its cash runway has been extended through the end of next year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.